Alleviare India Logo

How does an early access program work?

How does an early access program work?

Named patient programs are those which provide access of those medicines to the patients and physicians which are not available in their own country. It permits pharmaceuticals and Biotech companies to post permit the medicines or drugs that no longer exist in the market or are not in the clinical trials for a long time. These drugs must be approved in at least one country from which it can be exported to other countries in need. The thriving need has led to the development of an early access program or named patient sales or expended access programs.

These early access programs or named patient sales are authorized country specific regulatory tools that allow patients with unmet medical needs to have drug access before its launch. An EAP has a list of the benefits in pharmaceuticals consulting services; however, it should be dealt with utmost care by adapting following points :

 A regulatory team of EAP assures the level of authentic knowledge they hold before launching any named patient medicine.

 EAP shows major concern for potential safety issues, especially when the drug is ought to be misused under the name of the physician.

 Named patient supply is difficult to estimate in EAP as compared to the typical clinical trials, thus proper assessment of drugs and its production is made in order to meet the demand accordingly.

 Marketing and commercial team prohibits the promotion and set the right price which should match according to the varied countries’ prices (almost close to the right price at the time of launch).

 Furthermore, if one asks for the worthiness of EAP – it always seems to be great in named patient programs.

New skin cancer medicines announced under Named Patient Program

New skin cancer medicines announced under Named Patient Program

Skin cancer is caused as a result of genetic mutation, reduced immune functioning and some anomalous abrasions in the cells. Much prudent on its part, the skin oncology field has designed new skin cancer medicines that share a major link between internal scaffolding and nodding pathways that activate the abnormal growth of carcinogenic cells. This hidden perpetrator causes unusual genetic mutation, in the absence of the newly designed drugs.

Furthermore, after various explicit clinical trials on mice, oncology department approves that the rapidly proliferating oncogenic cell gets inhibited with the skin cancer medicines introduced for the purpose. It triggers the check point and obstructs the counter acts of the cancer cells at that point. The basic functioning of the newly defined skin cancer medicine is based on the interruption, no matter whatever the type (Merkel cell or basal cell) of carcinoma it may be.

Avelumab, when used along with other skin cancer medicines emerges as an important treatment in the skin cancer. However, the medicine is not available worldwide and is distributed through the named patient program. Pharmaceutical consulting services approve Avelumab along with some limitations to be concerned for its introduction to children below 12 years of age and women during pregnancy.

Avelumaba named patient medicine was not available in India earlier, however, the named patient supply is there to meet the demands of the skin cancer patients. It is also available in the name of Bavenico and on the valid clinical prescription only.

Hematology treatment through Named Patient Program

Hematology treatment through Named Patient Program

Hematology is the study concerned with analysis, treatment, cause and prevention from diseases related to blood. Blood related diseases affect the production of blood cells, red blood cells and white blood cells, plasma, hemoglobin, bone marrow, spleen and disrupt the coagulation mechanism. Hematology is generally meant to diagnose and treat malignant and benign disorders of blood and its components. Some serious, deadly diseases which may occur because of hematological disorders are Leukemia, myeloma and lymphoma that require chemotherapy at advanced stages.

The feasible treatment also includes coagulation treatment, transfusion of blood and medical treatment. The former two become obligatory when medicinal treatment does not respond or when the disease alleviates from the initial stage. However, why wait for severe condition to happen spending at costlier treatment.

Alleviare Life Sciences and pharmaceutical consulting company, supplies named patient medicines of Hematology malignancy medicine in Delhi at a cheaper rate. All these medicines are standardized and approved through the Medical Association. Named patient supplies of Alleviare Life Sciences, offers named patient medicines like MabCampth to treat B-cell chronic lymphocytic leukemia (B-CLL), a sort of cancer of white blood cells called B lymphocyte and Normosang to treat sudden attacks in patients suffering acute hepatic porphyria.

Many other named patient medicines are available in the market like Eltromobopag to treat chronic immune thrombocytopenia and Ibrutinib to treat Mantle Cell Lymphoma. Alleviare Life Sciences provides the delivery of cancer treatment medicines on time and anywhere in the world. These medicines are available on valid prescription of clinician and can be imported only if permit is applicable.